In one series of patients with metastatic tRCC treated with a VEGFR- or mTOR-targeted agent, the median PFS of the 21 patients who received sunitinib was 8.2 months (95% confidence interval, 2.6–14.7) [9]. Here, MTOR is linked to renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.